Immunosuppression for membranous nephropathy

摘要

The study by Andrew Howman and colleagues1 comparing two immunosuppression regimens with standard medical practice for the treatment of progressive idiopathic membranous nephropathy (IMN) represents a substantial advance for this disease. The authors are to be congratulated because nephrology has the fewest number of clinical trials of the major specialties,2 and few treatments enhance clinical outcomes.3 However, we wish to raise several points.